FindTrial
Sign In

Construction and validation of a survival prognosis evaluation model for glioma based on clinical molecular features and postoperative residual tumor

Construction and validation of a survival prognosis evaluation model for glioma based on clinical molecular features and postoperative residual tumor

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096087
Enrollment
Unknown
Registered
2025-01-17
Start date
2025-01-30
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

retrospective group:None
prospective group:None

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a clear pathological diagnosis confirmed to be glioma. 2. Patients aged over 18 years old and under 80 years old.

Exclusion criteria

Exclusion criteria: 1. Tumors in the cerebellum or brainstem. 2. Inability to undergo magnetic resonance imaging (such as having a pacemaker implanted, etc.). 3. History of other primary malignant tumors within the past five years. 4. Inability to obtain follow up data.

Design outcomes

Primary

MeasureTime frame
Overall survival;Progression free survival;—

Secondary

MeasureTime frame
epileptic seizure;Karnofsky Performance Status Score;motor function;language function;adjuvant therapy;quality of life;—

Countries

China

Contacts

Public ContactZhang Wei

Beijing Tiantan Hospital, Capital Medical University

zhangwei_vincent@mail.ccmu.edu.cn+86 137 0107 2976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026